• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Aclarion Inc.

    9/5/24 4:19:39 PM ET
    $ACON
    Medical Specialities
    Health Care
    Get the next $ACON alert in real time by email
    SC 13G 1 ea0213681-13greda_aclarion.htm SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No._)*

     

    Aclarion, Inc.
    (Name of Issuer)

     

    Common Stock, $0.00001 par value per share
    (Title of Class of Securities)

     

    655187201
    (CUSIP Number)

     

    August 27, 2024
    (Date of Event Which Requires Filing of this Statement)

       

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐Rule 13d-1(b)

     

    ☒Rule 13d-1(c)

     

    ☐Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 655187201
     
    (1)

    Names of reporting persons

    Joseph Reda

       
       
    (2) Check the appropriate box if a member of a group (see instructions)
      (a) ☐
      (b) ☐
       
       
    (3) SEC use only
       
       
    (4)

    Citizenship or place of organization

    United States

       
       
      Number of shares beneficially owned by each reporting person with:
         
      (5)

    Sole voting power

    500,000

         
         
      (6)

    Shared voting power

    500,000

         
         
      (7)

    Sole dispositive power

    500,000

         
         
      (8)

    Shared dispositive power

    500,000

         
       
    (9)

    Aggregate amount beneficially owned by each reporting person

    1,000,000

       
       
    (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)
       
       
    (11)

    Percent of class represented by amount in Row (9)

    9.9 % (1)

       
       
    (12)

    Type of reporting person (see instructions)

    IN

       

     

    (1)Based on 10,035,671 shares of Common Stock of the Issuer outstanding after the closing of the Common Stock Offering of shares of Common Stock of the Issuer, as verified with the Issuer on September 4, 2024.

     

    2

     

     

    CUSIP No. 655187201
     
    (1)

    Names of reporting persons

    SEG Opportunity Fund, LLC

       
       
    (2) Check the appropriate box if a member of a group (see instructions)
      (a) ☐
      (b) ☐
       
       
    (3) SEC use only
       
       
    (4)

    Citizenship or place of organization

    New York

       
       
      Number of shares beneficially owned by each reporting person with:
         
      (5)

    Sole voting power

    0

         
         
      (6)

    Shared voting power

    500,000

         
         
      (7)

    Sole dispositive power

    0

         
         
      (8)

    Shared dispositive power

    500,000

         
       
    (9)

    Aggregate amount beneficially owned by each reporting person

    500,000

       
       
    (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)
       
       
    (11)

    Percent of class represented by amount in Row (9)

    4.9% (1)

       
       
    (12)

    Type of reporting person (see instructions)

    OO

       

     

    (1)Based on 10,035,671 shares of common stock of the Issuer outstanding after the closing of the Common Stock Offering of shares of Common Stock of the Issuer, as verified with the Issuer on September 4, 2024.

     

    3

     

     

    ITEM 1(A) NAME OF ISSUER: Aclarion, Inc. (the “Issuer”)

     

    ITEM 1(B) ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:

     

    8181 Arista Place Suite 100

    Broomfield, Colorado 80021

     

    ITEM 2 (A) NAME OF PERSON FILING:

     

    This statement is jointly filed by and on behalf of each of Joseph Reda and SEG Opportunity Fund, LLC, a New York limited liability company (“SEG”, and together with Mr. Reda, “Reporting Persons”). Mr. Reda is the manager of, and may be deemed to beneficially own securities beneficially owned by, SEG. Mr. Reda and SEG are the record and direct beneficial owners of the shares of Common Stock of the Issuer covered by this statement.

     

    Each Reporting Person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement.

     

    Each Reporting Person may be deemed to be a member of a group with respect to the Issuer or securities of the Issuer for the purpose of Section 13(d) or 13(g) of the Act. Each of the Reporting Persons declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purpose of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any group with respect to the Issuer or any securities of the Issuer.

     

    ITEM 2 (B) ADDRESS OR PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

     

    The address of the principal business office of each of the Reporting Persons is 1 Wolfs Lane Suite 316 Pelham, NY 10803

     

    ITEM 2 (C) CITIZENSHIP:

     

    Joseph Reda is a citizen of the United States. SEG is a New York limited liability company.

     

    ITEM 2 (D) TITLE OF CLASS OF SECURITIES: Common Stock, $0.00001 par value per share (“Common Stock”)

     

    ITEM 2 (E) CUSIP NO.: 655187201

     

    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO §§ 240.13D-1(B) OR 240.13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A:

     

    (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

     

    (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

     

    (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

     

    (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

     

    (e) ☐ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

     

    (f) ☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

    4

     

     

    (g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     

    (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

    (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

    (j) ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

     

    (k) ☐ Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

    ITEM 4. OWNERSHIP 

     

    (a) Amount beneficially owned: See Item 9 on the cover pages(s) hereto.

     

    (b) Percent of class: See Item 11 on the cover page(s) hereto.

     

    (c) Number of shares as to which the person has:

     

    (i) Sole power to vote or to direct the vote See Item 5 on the cover pages hereto.

     

    (ii) Shared power to vote or to direct the vote See Item 6 on the cover pages hereto.

     

    (iii) Sole power to dispose or to direct the disposition of See Item 7 on the cover pages

    hereto.

     

    (iv) Shared power to dispose or to direct the disposition of See Item 8 on the cover

    pages hereto.

     

    ITEM 5. OWNERSHIP OF 5 PERCENT OR LESS OF A CLASS.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.

     

    ITEM 6. OWNERSHIP OF MORE THAN 5 PERCENT ON BEHALF OF ANOTHER PERSON.

     

    N/A

     

    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON.

     

    N/A

     

    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP

     

    N/A

     

    ITEM 9. NOTICE OF DISSOLUTION OF GROUP.

     

    N/A

     

    ITEM 10. CERTIFICATIONS

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    5

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: September 5, 2024

     

      JOSEPH REDA
         
      /s/ Joseph Reda
         
      SEG OPPORTUNITY FUND, LLC
         
      By: /s/ Joseph Reda
      Name: Joseph Reda
      Title: Manager

     

    6

     

     

    EXHIBIT INDEX

     

    Exhibit   Description of Exhibit
    99.1   Joint Filing Agreement (filed herewith).

     

     

    7

     

     

    Get the next $ACON alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACON

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ACON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Aclarion Inc.

      SC 13G/A - Aclarion, Inc. (0001635077) (Subject)

      11/13/24 3:06:29 PM ET
      $ACON
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Aclarion Inc.

      SC 13G - Aclarion, Inc. (0001635077) (Subject)

      9/5/24 4:19:39 PM ET
      $ACON
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Aclarion Inc. (Amendment)

      SC 13G/A - Aclarion, Inc. (0001635077) (Subject)

      3/29/24 5:00:57 PM ET
      $ACON
      Medical Specialities
      Health Care

    $ACON
    SEC Filings

    See more
    • SEC Form 10-Q filed by Aclarion Inc.

      10-Q - Aclarion, Inc. (0001635077) (Filer)

      5/15/25 7:54:10 AM ET
      $ACON
      Medical Specialities
      Health Care
    • SEC Form DEF 14A filed by Aclarion Inc.

      DEF 14A - Aclarion, Inc. (0001635077) (Filer)

      5/12/25 8:27:41 PM ET
      $ACON
      Medical Specialities
      Health Care
    • SEC Form EFFECT filed by Aclarion Inc.

      EFFECT - Aclarion, Inc. (0001635077) (Filer)

      5/6/25 12:15:15 AM ET
      $ACON
      Medical Specialities
      Health Care

    $ACON
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aclarion Adds UHealth, University of Miami Miller School of Medicine as CLARITY Trial Site

      UHealth — University of Miami Health System and the University of Miami Miller School of Medicine provide world-class research and renowned clinical expertise in spine surgeryCLARITY is a prospective, randomized clinical trial designed to demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., June 10, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI

      6/10/25 6:00:00 AM ET
      $ACON
      Medical Specialities
      Health Care
    • Aclarion Announces Addition of Keck Medical Center of USC as CLARITY Trial Site

      USC Spine Center, part of Keck Medicine of USC, specializes in treating complex spine conditions with the latest cutting-edge technologiesCLARITY is a randomized clinical trial designed to demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., May 20, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location

      5/20/25 6:00:00 AM ET
      $ACON
      Medical Specialities
      Health Care
    • Aclarion Announces Texas Back Institute as New CLARITY Trial Site

      Texas Back Institute is a world leader in advancing spine technology, science, and education, as well as patient careCLARITY is a randomized clinical trial designed to demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., May 12, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back

      5/12/25 7:34:07 AM ET
      $ACON
      Medical Specialities
      Health Care

    $ACON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Thramann Jeffrey John

      4 - Aclarion, Inc. (0001635077) (Issuer)

      3/28/23 8:30:04 PM ET
      $ACON
      Medical Specialities
      Health Care
    • SEC Form 4: Thramann Jeffrey John bought $1,000 worth of Series A Preferred Stock (1 units at $1,000.00)

      4 - Aclarion, Inc. (0001635077) (Issuer)

      2/21/23 4:02:40 PM ET
      $ACON
      Medical Specialities
      Health Care
    • SEC Form 4: Ness Brent bought $9,769 worth of shares (18,500 units at $0.53), increasing direct ownership by 1,850% to 19,500 units

      4 - Aclarion, Inc. (0001635077) (Issuer)

      12/29/22 7:57:11 PM ET
      $ACON
      Medical Specialities
      Health Care

    $ACON
    Leadership Updates

    Live Leadership Updates

    See more
    • Aclarion Launches Second Clinical Utility and Economic (CLUE) Trial Site With First Surgeon in New Jersey

      CLUE is a Multi-center Trial to Identify how Often Nociscan's AI Data Changes the Initial Treatment Plan for Patients With Chronic Low Back Pain Dr. Justin Kubeck Will Initiate CLUE in New Jersey at Ocean Pain and Spine in Toms River BROOMFIELD, CO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today the expansion of the multi-center CLUE Trial to New Jersey. Justin Kubeck, MD, orthopedic spine surgeon and founder of Ocean Pain and Spine in Toms

      8/29/24 6:57:00 AM ET
      $ACON
      Medical Specialities
      Health Care
    • Aclarion Appoints Nicholas Theodore, MD as Principal Investigator for CLARITY Post-Market Trial Evaluating Nociscan in the Diagnosis and Treatment of Chronic Low Back Pain

      Nicholas Theodore, MD, FACS, FAANS, is Director of Neurosurgical Spine Center, Johns Hopkins, and Professor of Neurosurgery, Orthopaedics and Biomedical Engineering CLARITY is a Post-market, Multi-site Trial That Will Further Evaluate the Role of Nociscan in the Diagnosis and Surgical Ttreatment of Chronic Low Back Pain. CLARITY is Targeted to Begin in the Second Half of 2023. BROOMFIELD, CO, May 02, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pa

      5/2/23 7:00:00 AM ET
      $ACON
      Medical Specialities
      Health Care
    • Aclarion Appoints George Frey MD as Seventh Key Opinion Leader Surgeon Advisor

      Broomfield, CO, Jan. 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc. ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW))), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that George Frey MD, Founder of the Colorado Comprehensive Spine Institute, will advise the company as a key opinion leader (KOL). Dr. Frey is a renowned surgeon and inventor with dozens of US and worldwide patents in medical devices, technologies, and methods. Dr. Frey's experiences as a clinician and entrepreneur will provide valuable direction to Aclarion.

      1/17/23 8:29:31 AM ET
      $ACON
      Medical Specialities
      Health Care